Clinical Trials Logo

Dyspepsia clinical trials

View clinical trials related to Dyspepsia.

Filter by:

NCT ID: NCT02113527 Completed - Dyspepsia Clinical Trials

Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia

DYSMOT-RIII
Start date: April 2014
Phase: N/A
Study type: Observational

Rome III criteria defined functional dyspepsia (FD) as the presence of symptoms from the gastroduodenal region in the absence of any organic, systemic or metabolic disease that is likely to explain the symptoms. FD can be further subdivided into two diagnostic categories: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Disorders of gastric electric activity and abnormal gastric emptying are probably actively involved in the FD onset. Different noninvasive procedures may be applied in order to evaluate the gastric motor functions such as 13C breath testing and cutaneous electrogastrography. Besides, different gastrointestinal peptides (i.e. CCK, peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II) are involved in the control of gastroduodenal motility. Aims of the present study are: 1) to evaluate the GI peptide circulating concentrations, the gastric electrical activity and gastric emptying time by applying noninvasive procedures in patients suffering from functional dyspepsia and 2) to test whether a significant difference exists between the two diagnostic categories of meal-induced dyspeptic symptoms

NCT ID: NCT02091635 Completed - Dyspepsia Clinical Trials

Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method

Start date: August 2013
Phase: N/A
Study type: Interventional

Functional dyspepsia (FD) is a disorder characterized by chronic or recurrent upper abdominal pain or discomfort in the absence of a specific structural cause. Improving gastric accommodation and prokinetic effect seem to be an attractive physiological target in patients with FD. Motilitone (Dong-A ST, Yongin, Korea) is a new herbal drug that was launched in December 2011 in Korea for treating patients with FD. The current study aims to evaluate effects of motilitone on gastric accommodation and emptying after a meal in a group of healthy volunteers using three-dimensional gastric volume measurements by magnetic resonance imaging (MRI). Healthy volunteers are randomly allocated to receive either motilitone or placebo in a double blinded manner. After 5 days of treatment, subjects undergo gastric MRI. The primary endpoint is gastric accommodation.

NCT ID: NCT02051348 Completed - Clinical trials for HELICOBACTER INFECTION

Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion

Start date: January 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Helicobator pylori (H. pylori) is a bacteria which survives in the lining of the stomach. An estimated 50% of the world's population is infected with H. pylori. Developing economies, such as in Southeast Asia, the Indian subcontinent and Latin America, have prevalence rates of as high as 90%. H. pylori infection often goes undiagnosed, as many sufferers do not experience any adverse symptoms. Infection with H. pylori is described as "not a disease in itself but a condition that affects the relative risk of developing various clinical disorders of the upper gastrointestinal tract.' Clinically relevant symptoms could include peptic ulcer, melena or secondary conditions such as iron deficiency anemia or vitamin B12 deficiency. There is evidence that probiotics can be beneficial for those with gastrointestinal diseases. Pylopass contains the probiotic strain Lactobacillus reuteri, which was selected for its anti-H. pylori characteristics and in clinical trials has shown to result in a reduction in urease breath test values in subjects with H. pylori. The objective of this study is to evaluate the ability of Pylopass to reduce H. pylori load in subjects who are H. pylori positive.

NCT ID: NCT02037776 Completed - Clinical trials for Functional Dyspepsia

The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia

Start date: April 3, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Rikkunshito compared to placebo in Japanese subjects with Functional Dyspepsia (FD).

NCT ID: NCT01990339 Completed - Clinical trials for Gastroesophageal Reflux Disease With Dyspepsia Symptoms

Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms

LEGEND
Start date: December 2008
Phase: N/A
Study type: Observational

To evaluate the efficacy of 4-week lansoprazole (Takepron) therapy for subjective symptomatic improvement in gastroesophageal reflux disease patients with dyspepsia symptoms

NCT ID: NCT01980095 Completed - Clinical trials for Helicobacter Pylori Infection

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

ERADICATE Hp
Start date: November 2013
Phase: Phase 3
Study type: Interventional

The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients.

NCT ID: NCT01973790 Completed - Dyspepsia Clinical Trials

Phase III, Long-term, Open-label Safety Study of Z-338

Start date: March 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety of 100 mg Z-338 TID in European subjects with FD.

NCT ID: NCT01915173 Completed - Dyspepsia Clinical Trials

Response to Supplement and Placebo in GERD

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux disease (GERD). This study is designed as a pilot trial to assess safety and feasibility and to provide preliminary estimates of effect sizes.

NCT ID: NCT01888237 Completed - Dyspepsia Clinical Trials

High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication

Start date: May 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy between 1-day high dose PPI-based triple therapy vs. 10-day sequential therapy for Helicobacter pylori eradication in functional dyspepsia patients.

NCT ID: NCT01869491 Completed - Clinical trials for Gastroesophageal Reflux Disease

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

Start date: June 2013
Phase: Phase 3
Study type: Interventional

This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).